Regeneron Drug Reduced Weight-Loss Muscle Mass Loss
A clinical trial showed that adding trevogrumab to semaglutide therapy cut muscle loss in half for patients.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Would you prioritize taking a weight-loss drug that specifically preserves muscle mass over other options?
In a clinical trial involving nearly 1,000 patients, Regeneron reported that their experimental drug trevogrumab reduced lean muscle mass loss by 50% when used alongside semaglutide. The study aimed to enhance the quality of weight reduction by mitigating the muscle atrophy often associated with rapid weight loss.
Why it matters
Preserving muscle mass during weight loss is a key goal for improving health outcomes, as existing treatments like semaglutide can cause significant muscle depletion. Developing therapies that target this issue could revolutionize the effectiveness of weight-management programs.
The study found patients taking 75 milligrams of trevogrumab lost 3.3% of lean muscle mass compared to 6.7% for those on semaglutide alone over 26 weeks. Researchers measured these changes using MRI scans of thigh muscle mass in the trial cohort.
The players
Regeneron
Regeneron is a major biotechnology company that discovers, develops, and manufactures medicines for serious medical conditions.
The details
Trevogrumab functions by inhibiting the protein myostatin, which naturally regulates muscle growth. While the drug showed promise in preserving muscle, Regeneron discontinued a separate triple-combination study involving trevogrumab and garetosmab after two participants died.
Timeline
26 weeks was the trial measurement period for muscle mass loss.
52 weeks is the target measurement period for 75mg trevogrumab muscle preservation.
Thursday, September 24, 2026, was the date data was presented at a conference in Milan.
2035 is the projected year for reaching $30 billion in annual therapy sales.
The Big Picture
This discovery updates the clinical framework established by the ongoing development of GLP-1 receptor agonists. It represents a shift toward dual-action therapies that aim to preserve lean tissue while promoting fat loss.
Patients currently managing weight loss with semaglutide may eventually have access to supplemental therapies that prevent muscle wasting. This could allow individuals to maintain higher metabolic rates and physical strength during their weight-reduction journey.
The takeaway
Weight-loss therapies are evolving to focus on body composition rather than just total scale weight. This shift emphasizes the importance of protecting muscle mass to ensure sustainable and healthy weight reduction results.
What happens next
Regeneron plans to initiate a new mid-stage clinical trial specifically for patients over the age of 65.
Further reading
Learn more about the latest developments in Weight Loss treatments.
Live Poll
Would you prioritize taking a weight-loss drug that specifically preserves muscle mass over other options?
